+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 5017395
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 141 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AbbVie
  • Mustang Bio
  • Stemline Therapeutics
  • Xencor
  • MORE
‘Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted BPDCN symptoms market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Blastic plasmacytoid dendritic cell neoplasm (BPDCN) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Disease Understanding and Treatment Algorithm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare entity grouped with the acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. It is a clinically aggressive tumor that often initially presents as cutaneous lesions and subsequently progresses to bone marrow involvement and leukemic dissemination characterized by enhanced expression of CD56, CD4, and CD123.

Patients with BPDCN have diverse clinical features, with cutaneous tumors in nearly all cases; the high incidence of such tumors distinguishes this disease from other myeloid cancers. Other sites of involvement include bone marrow, peripheral blood, lymph nodes, spleen, and other extramedullary organs. BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with such diseases and skin lesions should be evaluated for BPDCN specifically.

BPDCN can be referred by different names such as blastic NK cell lymphoma, agranular CD4+ NK cell leukemia, blastic NK leukemia/lymphoma, and agranular CD4+ CD56+ hematodermic neoplasm. Also, as per WHO 2016 classification, BPDCN is currently classified as a distinct entity within the myeloid neoplasm and acute leukemia classification.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe, and Japan.

The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market report gives a thorough understanding of BPDCN symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides BPDCN symptoms of treatment algorithms and treatment guidelines for BPDCN symptoms in the US, Europe, and Japan.

The diagnosis of BPDCN has evolved as clinical and pathological technologies have improved and enhanced. A series of molecular studies based on karyotyping, gene expression profiling, and next generation sequencing, have largely unveiled the pathobiology of the tumour and proposed the potentially beneficial use of new drugs. Intensified chemotherapy with or without stem cell transplantation showed an objective response. The differential diagnoses include myeloid sarcoma/acute myeloid leukemia, T-cell lymphoblastic leukemia/lymphoma, NK-cell lymphoma/leukemia, and some mature T-cell lymphomas/leukemias. Along with this, with the improved identification of mutation and biomarkers, recently, targeted therapies have come into the attention.

The FDA has approved Stemline Therapeutics' tagraxofusp-erzs (Elzonris), targeting CD123 as the first drug approved to treat BPDCN.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Epidemiology

The BPDCN symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The diagnosed incident cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is increasing in 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted BPDCN symptoms epidemiology segmented as the Total Incident cases of BPDCN, Gender-Specific cases of BPDCN, Age-Specific cases of BPDCN. The report includes the incident scenario of BPDCN symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Epidemiology

The epidemiology segment also provides the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total incident population of BPDCN in 7MM countries was estimated to be 1,786 cases in 2017.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Drug Chapters

The drug chapter segment of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) report encloses the detailed analysis of BPDCN marketed drugs and early stage (Phase-II and Phase-I) pipeline drugs. It also helps to understand the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Emerging Drugs

MB-102: Mustang Bio
MB-102 (CD123 CAR T) is a CAR T cell therapy that is produced by engineering patient T cells to recognize and eliminate CD123-expressing tumors. CD123 is widely expressed on bone marrow cells of patients with myelodysplastic syndromes, as well as in hematologic malignancies, including AML, B-cell acute lymphoblastic leukemia, hairy cell leukemia, BPDCN chronic myeloid leukemia and Hodgkin's lymphoma. Currently Mustang Bio is conducting Phase I/II clinical studies for BPDCN, AML and MDS. The FDA granted Orphan Drug Designation to MB-102 (CD123 CAR T) 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm.

Products detail in the report.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Market Outlook

The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market in 7MM is expected to grow in the study period 2017-2030.

There is no established standard therapy for BPDCN, and the efficacy of conventional chemotherapy is limited, with an anticipated median overall survival less than a year, if left untreated. Due to the lack of prospective clinical trials, there had been no universally accepted standard of care.

Tagraxofusp is a CD123 directed recombinant fusion protein, which leads to translocation of the diphtheria toxin fragment to the cytosol, followed by ADP ribosylation of elongation factor 2, with the resultant cessation of protein synthesis and cell death.

Patients with BPDCN may also be treated with regimens derived from the management of more common hematological malignancies, including non-Hodgkin lymphoma (cyclophosphamide/hydroxydaunomycin/vincristine/prednisone [CHOP] or [CHOP-like], acute lymphoblastic leukemia [ALL]; hyperfractionated/cyclophosphamide/vincristine/ doxorubicin/dexamethasone [hyper-CVAD] alternating with methotrexate and cytarabine), and AML. Autologous (auto) or allo-HCT (Hematopoietic cell transplantation) has been utilized as consolidative therapy in patients with BPDCN.

Key Findings

This section includes a glimpse of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market in 7MM. The market size of BPDCN in the seven major markets was found to be USD 17.79 million in 2017.

The United States Market Outlook

This section provides the total Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market size and market size by therapies in the United States.

The United States accounts for the highest market size of BPDCN in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market size and market size by therapies in Japan are also mentioned.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase I, and Phase II stage. It also analyses Blastic plasmacytoid dendritic cell neoplasm (BPDCN) key players involved in developing targeted therapeutics.

Major players include AbbVie, Mustang Bio, Xencor, Inc and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) emerging therapies.

Reimbursement Scenario in BPDCN

Approaching reimbursement proactively can have a positive impact both during the early stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

Aggressive chemotherapy followed by allogeneic stem cell transplantation (ASCT) is a favorable treatment plan for BPDCN. Most health plans cover these therapies under medical benefit. Medicare Part B covers Elzonris injection for IV use in the outpatient setting. As an infused drug, Elzonris injection for IV use is not covered under Medicare Part D benefit. Stemline ARC Reimbursement policy help eligible patients with reimbursement support for Elzonris injection for intravenous (IV) use

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of BPDCN, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
Report Highlights
  • In the coming years, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Blastic plasmacytoid dendritic cell neoplasm (BPDCN) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for BPDCN. Launch of emerging therapies will significantly impact the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
- Our in-depth analysis of the pipeline assets across different stages of development (Phase I and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Blastic plasmacytoid dendritic cell neoplasm (BPDCN)Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Pipeline Analysis
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What were the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the BPDCN?
  • What is the historical Blastic plasmacytoid dendritic cell neoplasm (BPDCN)patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Blastic plasmacytoid dendritic cell neoplasm (BPDCN)in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to BPDCN?
  • Out of all 7MM countries, which country would have the highest incident population of Blastic plasmacytoid dendritic cell neoplasm (BPDCN)during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN)along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN)in the USA, Europe, and Japan?
  • What are the Blastic plasmacytoid dendritic cell neoplasm (BPDCN)marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of BPDCN?
  • How many therapies are developed by each company for the treatment of BPDCN?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of BPDCN?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Blastic plasmacytoid dendritic cell neoplasm (BPDCN)therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Blastic plasmacytoid dendritic cell neoplasm (BPDCN)and their status?
  • What are the key designations that have been granted for the emerging therapies for BPDCN?
  • What are the global historical and forecasted market of BPDCN?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
  • To understand the future market competition in the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
  • To understand the future market competition in the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Mustang Bio
  • Stemline Therapeutics
  • Xencor
  • MORE
1. Key Insights

2. Executive summary

3. Organizations

4. Epidemiology and Market Methodology

5. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Market Overview at a Glance
5.1. Total Market Share (%) Distribution of BPDCN in 2017
5.2. Total Market Share (%) Distribution of BPDCN in 2030

6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Disease Overview
6.1. Introduction
6.2. Classification
6.3. Clinical Presentation
6.4. Pathogenesis
6.5. Diagnosis

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM
7.3. United States
7.3.1. Assumptions and Rationale
7.3.2. Total Incident cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.3.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.3.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.4. EU5 Countries
7.5. Assumptions and Rationale
7.6. Germany
7.6.1. Assumptions and Rationale
7.6.2. Total Incident cases of BPDCN in Germany
7.6.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Germany
7.6.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in Germany
7.7. France
7.7.1. Assumptions and Rationale
7.7.2. Total Incident cases of BPDCN in France
7.7.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in France
7.7.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm France
7.8. Italy
7.8.1. Total Incident cases of BPDCN in Italy
7.8.2. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Italy
7.8.3. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in Italy
7.9. Spain
7.9.1. Total Incident cases of BPDCN in Spain
7.9.2. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Spain
7.9.3. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm Spain
7.10. UK
7.10.1. Total Incident cases of BPDCN in the United Kingdom
7.10.2. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United Kingdom
7.10.3. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasmin the United Kingdom
7.11. Japan
7.11.1. Assumptions and Rationale
7.11.2. Total Incident cases of BPDCN in Japan
7.11.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Japan
7.11.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in Japan

8. Current Treatment Practices
8.1. Treatment Algorithm

9. Unmet Needs

10. Marketed drugs

11. Elzonris: Stemline Therapeutics
11.1. Drug Description
11.2. Regulatory Milestones
11.3. Other Development Activities
11.4. Clinical Development
11.5. Safety and Efficacy
11.6. Product Profile

12. Emerging Therapies

13. Key Cross Competition

14. MB-102: Mustang Bio
14.1. Product Description
14.2. Other Developmental Activities
14.3. Clinical Development
14.4. Safety and Efficacy
14.5. Product Profile

15. IMGN632: ImmunoGen/ Jazz Pharmaceuticals
15.1. Drug Description
15.2. Clinical Development
15.3. Safety and Efficacy
15.4. Product Profile

16. UniCAR02-T-CD123: Cellex Patient Treatment GmbH
16.1. Drug Description
16.2. Other Developmental Activities
16.3. Clinical Development
16.4. Product Profile

17. Venetoclax: AbbVie
17.1. Drug Description
17.2. Other Developmental Activities
17.3. Clinical Development
17.4. Safety and Efficacy
17.5. Product Profile

18. XmAb14045: Xencor
18.1. Drug Description
18.2. Other Developmental Activities
18.3. Clinical Development
18.4. Safety and Efficacy
18.5. Product Profile

19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 7 Major Market Analysis
19.1. Key Findings
19.2. Market Size of Blastic plasmacytoid dendritic cell neoplasm in 7MM

20. Seven Major Market Outlook
20.1. United States Market Size
20.1.1. Total Market Size of Blastic plasmacytoid dendritic cell neoplasm in the United States
20.1.2. Total Market Size of Blastic plasmacytoid dendritic cell neoplasm by Line of Therapies in the United States
20.2. Germany
20.2.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Germany
20.2.2. Total market size of Blastic plasmacytoid dendritic cell neoplasm by Line of Therapies in Germany
20.3. France
20.3.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in France
20.3.2. Total Market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in France
20.4. Italy
20.4.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Italy
20.4.2. Total Market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in Italy
20.5. Spain
20.5.1. Total Market Size of Blastic plasmacytoid dendritic cell neoplasm in Spain
20.5.2. Total market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in Spain
20.6. United Kingdom
20.6.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in the United Kingdom
20.6.2. Total market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in the UK
20.7. Japan

21. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Japan

22. Total market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in Japan

23. Market Drivers

24. Market Barriers

25. SWOT Analysis

26. Reimbursement policies
26.1. Current Therapies

27. Case Study
27.1. A Case Report of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
27.2. A Challenging Blastic Plasmacytoid Dendritic Cell Neoplasm Case

28. KOL Views

29. Appendix

30. Report Methodology

31. Capabilities

32. Disclaimer

33. About the Publisher

34. Bibliography
Note: Product cover images may vary from those shown
3 of 3
  • Stemline Therapeutics
  • Mustang Bio
  • ImmunoGen/ Jazz Pharmaceuticals
  • Cellex Patient Treatment GmbH
  • AbbVie
  • Xencor
Note: Product cover images may vary from those shown
Adroll
adroll